Bottom Line: Stop reading every PSA against a single 3.0 µg/L cut-off — check the patient’s age band and risk category first, raise the testing conversation yourself rather than waiting to be asked, and request mpMRI rather than a biopsy referral after a confirmed elevated result.
Why the PSA Testing Guidelines Changed
The 2016 Clinical practice guidelines for PSA testing and early management of test-detected prostate cancer, developed by Cancer Council Australia and the Prostate Cancer Foundation of Australia (PCFA), had been the reference point for Australian general practice for close to ten years. In that period the diagnostic pathway changed substantially: multiparametric MRI moved from an emerging tool to standard practice, transperineal biopsy displaced the transrectal approach in most centres, and active surveillance became accepted management for low-risk disease rather than an option requiring justification.
The development process was not without disagreement. The draft released for public consultation in mid-2025 proposed baseline PSA testing from age 40, and two-yearly testing from age 40 for Aboriginal and Torres Strait Islander men. The RACGP objected to both, arguing the evidence did not support a lower starting age for Aboriginal and Torres Strait Islander men and that testing from 40 risked greater harm from false positives and overdiagnosis. The final guidelines moved the general starting point to 45 and aligned recommendations for Aboriginal and Torres Strait Islander men with those for the general population. RACGP President Dr Michael Wright welcomed the outcome: “It’s good to see these new guidelines clear up some of the uncertainty in the previous guidelines.”
Australia still has no national population screening program for prostate cancer. What has changed is the framework for opportunistic early detection in general practice, which is now explicitly risk-adapted, age-banded and MRI-led.
The Change in Detail
The GP now initiates the discussion
The most significant practical shift is one of responsibility. Under the 2016 approach, PSA testing was patient-initiated: men who raised the question received a balanced discussion of benefits and harms. The 2026 guidelines recommend that GPs proactively raise PSA testing with eligible men as part of routine preventive care. Professor Peter Heathcote, who chaired the guideline development, described the shift as substantial: “Previously it was recommended that you talk to your doctor but now we’re recommending that GPs initiate that discussion — that’s an enormous change.”
Shared decision making remains the anchor. The guidelines are explicit that “informed discussion of the possible benefits and harms of PSA testing with shared decision making and patient choice is key to good clinical practice.” Documenting that discussion remains good medicolegal practice.
Who to test, and when
| Age band | Average risk | Higher risk |
|---|---|---|
| 45–49 | Routine testing not recommended. A baseline PSA may be offered to interested men after an informed discussion. | Offer testing every two years from 45. |
| 50–69 | Offer testing every two years after an informed discussion. | Offer testing every two years. |
| 70+ | Based on clinical assessment: offer where life expectancy exceeds approximately seven years, weighing comorbidities and the patient’s preferences. | As for average risk. |
A baseline result below 1.0 µg/L at ages 45–49 means no further PSA testing is recommended until age 50. Testing should cease when life expectancy is limited, or when comorbidities make prostate cancer treatment unlikely to improve quality or length of life — replacing the 2016 position, which effectively discouraged testing beyond age 70.
“Higher risk” is defined as at least double the general-population risk of dying from clinically significant prostate cancer, and includes men with:
- A brother diagnosed with prostate cancer
- A father diagnosed before age 65
- Two or more second-degree relatives who died from prostate cancer
- Black sub-Saharan African ancestry
- A confirmed BRCA2 pathogenic variant
For Aboriginal and Torres Strait Islander men, the final guidelines recommend the same age and risk-based pathway as for the general population, delivered through culturally appropriate discussion and resources and integrated into annual health assessments.
PSA action levels are now banded by age and risk
This is the change with the greatest day-to-day impact. The single 3.0 µg/L threshold no longer applies across the board.
| Age | Average risk | Higher risk |
|---|---|---|
| 45–49 | ≥ 1.0 µg/L | ≥ 1.0 µg/L |
| 50–69 | ≥ 3.0 µg/L | ≥ 2.0 µg/L |
| 70+ | ≥ 5.5 µg/L | ≥ 5.5 µg/L |
Where the action level is reached or exceeded, repeat the PSA within 1–3 months. If the elevation is confirmed, refer for further investigation. Where it is not reached:
- 45–49 below 1.0 µg/L — no further testing until age 50
- 50–69 below the relevant threshold — continue two-yearly testing
- 70+ below 5.5 µg/L — further testing may be discontinued
Digital rectal examination is out of primary care
The guidelines carry a conditional recommendation against DRE in this setting: “We suggest that digital rectal examination not be offered in the primary care setting as a routine addition to PSA testing and risk assessment.”
DRE retains a role in the specialist setting, particularly before a decision about biopsy. Removing it from the primary care pathway is intended to reduce a recognised barrier to men accepting testing at all.
Multiparametric MRI precedes biopsy
A good practice statement establishes the sequence: “For males requiring further investigation on the basis of their PSA, an mpMRI is recommended as their next diagnostic test.”
| mpMRI result | Recommended action |
|---|---|
| PI-RADS 4–5 | Offer biopsy — mpMRI-targeted plus systematic |
| PI-RADS 3 with PSA density ≥ 0.15 µg/L/mL | Offer biopsy — targeted plus systematic |
| PI-RADS 1–2 | Systematic biopsy may still be performed if there is clinical concern |
PSA density should be calculated from the most recent PSA result prior to the mpMRI. Where biopsy proceeds, an ultrasound-guided transperineal approach is preferred over transrectal because of the lower risk of post-biopsy infection. MRI triage is reported to avoid approximately half of the biopsies that would previously have been performed.
Active surveillance becomes the expected pathway for low-risk disease
The guidelines set an explicit expectation that more than 80% of men with low and very-low-risk disease are managed with active surveillance rather than immediate treatment. Typical criteria include ISUP grade group 1 only, PSA density ≤ 0.15 µg/L/mL, clinical stage T1c or T2a, ≤ 33% of cores involved, life expectancy ≥ 15 years, and capacity to comply with a monitoring protocol. Watchful waiting remains the conservative option for men with significant comorbidity or those declining intervention.
Clinical and Practical Implications
Of everything in the new PSA testing guidelines, the banded action levels are the change most likely to generate errors in the first months. A PSA of 2.4 µg/L in a 55-year-old is unremarkable at average risk but reaches the action level if that man has a brother with prostate cancer. Practices relying on pathology software to flag results against a single reference range will need a manual layer — a risk field in the patient record, or a habit of checking family history before interpreting the number.
The shift to GP-initiated discussion has workload consequences. Offering the conversation to every man aged 50–69 in a practice population is a meaningful volume of preventive care activity, competing with the same time pressures that already crowd out other opportunistic screening. Embedding the prompt into existing structures — health assessments, chronic condition reviews, or nurse-led preventive activity — is likely to prove more sustainable than relying on it arising during acute consultations.
The MRI-first pathway also changes what a referral needs to contain. Where a confirmed elevated PSA previously prompted a urology referral for consideration of biopsy, the expectation now is imaging first. Access and out-of-pocket cost for mpMRI vary considerably by location, and are worth discussing with the patient before the request is made.
What You Need to Do
Seven steps to bring your practice into line with the new PSA testing guidelines:
- Add a risk-status prompt to your preventive care workflow so family history, ancestry and known BRCA2 status are captured before a PSA is interpreted.
- Update any practice PSA protocol or recall template that references a single 3.0 µg/L action level to the banded 1.0 / 2.0 / 3.0 / 5.5 µg/L structure.
- Build the offer into structured consultations — health assessments, chronic disease reviews and nurse-led preventive activity — rather than relying on acute presentations.
- Repeat before referring. A result at or above the action level is repeated within 1–3 months; refer on the confirmed result.
- Request mpMRI, not a biopsy referral, as the next diagnostic step after a confirmed elevated PSA, and discuss likely access and cost with the patient.
- Review your over-70 cohort. The question is now life expectancy and comorbidity rather than age alone.
- Remove routine DRE from your PSA testing and risk assessment pathway in primary care.
Summary
- Effective: Released 6 August 2026, RACGP endorsed 10 August 2026 (NHMRC CEO approval 18 May 2026), replacing the 2016 Cancer Council Australia / PCFA guidelines
- Who initiates: GPs now proactively raise PSA testing with eligible men
- Ages: Baseline PSA may be offered from 45 at average risk; two-yearly testing 50–69; higher-risk men two-yearly from 45
- Higher risk: Brother affected, father diagnosed under 65, two or more second-degree relatives who died of prostate cancer, Black sub-Saharan African ancestry, or BRCA2
- Action levels: ≥1.0 µg/L (45–49), ≥3.0 µg/L average or ≥2.0 µg/L higher risk (50–69), ≥5.5 µg/L (70+) — repeat within 1–3 months, refer if confirmed
- Over 70: Offer where life expectancy exceeds approximately seven years; DRE no longer recommended as a routine addition in primary care
- Imaging: mpMRI before biopsy; PI-RADS 4–5, or PI-RADS 3 with PSA density ≥0.15 µg/L/mL, proceed to targeted plus systematic biopsy; transperineal preferred
- Management and review: Active surveillance expected in more than 80% of low-risk cases; Aboriginal and Torres Strait Islander men follow the same pathway with culturally appropriate delivery; PSA chapter expires 17 May 2028
Sources
- 2026 Guidelines for the Early Detection of Prostate Cancer in Australia — Prostate Cancer Foundation of Australia
- RACGP — 2026 Guidelines for the Early Detection of Prostate Cancer in Australia
- newsGP — RACGP endorses updated prostate cancer guideline
- newsGP — RACGP reacts to overhauled prostate cancer guidelines
- PCFA — New guidelines for the early detection of prostate cancer
This summary of the 2026 PSA testing guidelines is educational content for medical practitioners and is not a substitute for the full guideline or for individual clinical judgement. Verify recommendations against the source document before applying them to patient care.
